The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Invesco Mutual Fund
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Smallcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Invesco Mutual Fund (across six of its equity schemes) bought 5,50,000 shares of Sai Life Sciences in the open market on July 14, 2025. This raised its aggregate holding from 4.98% (1,03,91,723 shares) to 5.25% (1,09,41,723 shares) of the company's paid-up capital. The disclosure was filed under SEBI's SAST Regulation 29(1) because the acquisition pushed Invesco past the 5% disclosure threshold. Invesco is not part of the promoter group — it is an institutional investor. The share capital remains unchanged at 20.85 crore equity shares of Re.1 each.
A foreign institutional investor increasing its stake and crossing the 5% mark is a mild positive signal, indicating institutional confidence in Sai Life Sciences. However, the size of the incremental purchase (~0.26% stake) is small, so the direct stock price impact is likely limited.